

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- |    |  |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Medicines including gelatine may not be acceptable for some people from certain religious backgrounds. Avapritinib does not include gelatine and so may be a suitable option for these people, in the place of other medicines which do include gelatine.
---

- |    |  |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

The committee will appraise avapritinib within its marketing authorisation. The scope indicates avapritinib will be used as an add-on to current standard of care, but the committee would consider whether there are any relevant populations who may be unable to receive treatments containing gelatine and whether this required any adjustment to their recommendations or approach.
---

- |    |   |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No
----

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
	No

**Approved by Associate Director (name):** Lorna Dunning

**Date:** 22/09/25